You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform.
About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.
The French metagenomic sequencing firm received funding from both historical and new investors, including debt financing from Norgine Ventures.
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
The company is currently partnering with three medical firms to develop its nonlinear optical spectroscopy technology for biosensing and imaging applications.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
The Oakland, California-based company will use the funding to speed the manufacturing and commercialization of its dual alcohol and marijuana breathalyzer.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.
The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.